Table 1.

Randomised controlled trials in patients.

Drug	Year of publication	Inclusion	Outcome	Remarks
CYC plus AZA versus placebo	2006, RCT 34	45 SSc-ILD	No difference in outcome though trend towards significance in CYC group	38% lost to follow-up
Oral CYC versus AZA	2004, Unblinded RCT 35	60 SSc (30 each arm)	No change in FVC or DLCO in CYC group Deterioration in AZA group	Number of patients with ILD not mentioned
CYC versus placebo	2007, RCT 36	158 SSc-ILD (evaluated 72 CYC; 73 placebo)	Beneficial effects on PFT persisted only till 18 months though subjective effects on dyspnea perisisted for 2 years	Second year follow-up of SLS1 study
MMF vs CYC	2016, RCT 38	63 MMF; 63 CYC	No statistical difference in adjusted FVC between groups except greater number of withdrawals and failed treatment with CYC	Both MMF and CYC improved lung function, imaging, dyspnoea and skin disease